CAMBRIDGE,Mass.--(BUSINESS WIRE)--May 2, 2018--
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company
in the discovery and development of TGF-beta therapeutics to treat
serious and rare diseases, today announced that senior management will
participate in two upcoming healthcare investor conferences in May.
Event: Deutsche Bank 43rd Annual Health Care Conference
Tuesday, May 8, 2018
Location: Boston, MA
Event: UBS Global Healthcare Conference
Date/Time: Tuesday, May 22,
2018 at 1:30 p.m. EDT
Location: New York, NY
A live audio webcast for the UBS conference will be available on the
Investors/Media page of the Company's website at www.acceleronpharma.com.
A replay of the webcast will be available approximately two hours after
the event on the Acceleron website.
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company
dedicated to the discovery, development, and commercialization of
therapeutics to treat serious and rare diseases. The Company’s
leadership in the understanding of TGF-beta biology and protein
engineering generates innovative compounds that engage the body’s
ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in hematologic,
neuromuscular, and pulmonary diseases. In hematology, the Company and
its global collaboration partner, Celgene, are developing luspatercept
for the treatment of chronic anemia in myelodysplastic syndromes,
beta-thalassemia, and myelofibrosis. Acceleron is also advancing its
neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and
ACE-2494, and a pulmonary program with a Phase 2 trial of sotatercept
planned in pulmonary arterial hypertension.
For more information, please visit www.acceleronpharma.com/.
Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180502005192/en/
Source: Acceleron Pharma
Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
President, Investor Relations and Corporate Communications
Manager, Investor Relations and Corporate